Ampio Pharmaceuticals Aktie [WKN DE: A1JGFU / ISIN: US03209T1097]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Ampio Pharmaceuticals Inc

01.12.23		What's Going On With Ampio Pharmaceuticals Stock? (Benzinga)
31.10.23		Ampio Pharmaceuticals to Present at the Emerging Growth Conference (PR Newswire)
05.10.23		Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201 (PR Newswire)
26.09.23		Ampio Pharmaceuticals to Present at the Emerging Growth Conference (PR Newswire)
31.08.23		Ampio Pharmaceuticals Board Approves Reverse Stock Split - Quick Facts (RTTNews)
31.08.23		Ampio Pharmaceuticals Announces Reverse Stock Split (PR Newswire)
26.05.23		Ampio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common Stock (PR Newswire)
18.04.23		AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS (PR Newswire)
17.01.23		AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS (PR Newswire)
27.12.22		Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards (PR Newswire)
17.11.22		Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension (PR Newswire)
08.11.22		Ampio Pharmaceuticals Announces Fifteen-to-One Reverse Stock Split (PR Newswire)
16.10.22		AMPE DEADLINE TOMORROW: ROSEN, skilled investor counsel, Encourages Ampio Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important October 17 Deadline in Securities Class Act... (PR Newswire)
14.10.22		Ampio Pharmaceuticals Issues Letter to Stockholders (PR Newswire)
08.10.22		ROSEN, LEADING INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE (PR Newswire)
04.10.22		Ampio Pharmaceuticals Issues Letter to Stockholders (PR Newswire)
04.10.22		Ampio Pharmaceuticals Announces NYSE American Has Commenced Delisting Proceedings (PR Newswire)
28.09.22		ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE (PR Newswire)
15.09.22		ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE (PR Newswire)
09.09.22		AMPE LOSS ALERT: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE (PR Newswire)
02.09.22		ROSEN, A LEADING LAW FIRM, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE (PR Newswire)
24.08.22		AMPE SHAREHOLDER ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ampio Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMPE (PR Newswire)
03.08.22		Ampio Pharmaceuticals Issues Letter to Stockholders (PR Newswire)
02.06.22		Ampio Pharmaceuticals' CEO Mike Martino Issues Letter to Stockholders (PR Newswire)
16.05.22		Ampio Pharmaceuticals Reports First-Quarter Financial Results (PR Newswire)
16.05.22		Ampio Independent Committee to Conduct Investigation (PR Newswire)
27.04.22		Ampio Pharmaceuticals, Inc. to Hold Conference Call (PR Newswire)
20.04.22		AMPIO PROVIDES REGULATORY UPDATE (PR Newswire)
29.03.22		Ampio Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Operational Highlights (PR Newswire)
23.03.22		Ampio Pharmaceuticals, Inc. to Hold Fourth Quarter 2021 Earnings and Business Update Call (PR Newswire)
09.03.22		Ampio Pharmaceuticals to Participate at the 34th Annual Roth Conference (PR Newswire)
02.03.22		Ampio Pharmaceuticals, Inc. Releases Positive Phase 3 Data Analysis for Ampion™ Targeting Severe Osteoarthritis of the Knee (OAK) (PR Newswire)
02.03.22		Ampio Pharmaceuticals, Inc. to Host a Conference Call and Webinar (PR Newswire)
22.11.21		Ampio Pharma Chairman And CEO Mike Macaluso Taking One-year Medical Leave - Quick Facts (RTTNews)
15.09.21		Ampio : Ampion Shows Reduction In Pain & Improvement In Function At 12 Weeks In Severe OAK Patients (RTTNews)
13.08.21		Ampio Pharmaceuticals Announces Important New Research Manuscript on Anti-Inflammatory Mode of Action (PR Newswire)
12.08.21		Ampio Pharmaceuticals Reminds Stockholders to Vote Shares in Advance of 2021 Annual Meeting (PR Newswire)
11.08.21		Ampio Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences (PR Newswire)
04.08.21		Ampio Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update (PR Newswire)
29.07.21		Ampio Pharmaceuticals to Present at the American College of Toxicology 42nd Annual Meeting (PR Newswire)
28.07.21		Ampio Pharmaceuticals to Present at the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) & 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA) (PR Newswire)
27.07.21		Ampio Pharmaceuticals to Present at Aspen Lung Conference (PR Newswire)
14.07.21		Ampio Pharmaceuticals, Inc. to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Business Update (PR Newswire)
25.06.21		Ampio Pharmaceuticals Announces Patient Randomization and Dosing in AP-019 Phase II Study of Inhaled Ampion in COVID-19 Respiratory Distress (PR Newswire)
18.06.21		Ampio Pharmaceuticals, Inc. to Join the Russell 2000® Index and Russell 3000® Index (PR Newswire)
17.06.21		Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAK (PR Newswire)
15.06.21		Ampio Pharma Allowed To Extend Mid-stage Study Of Ampion In Covid-19 To India (RTTNews)
15.06.21		Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India (PR Newswire)
14.06.21		Ampio Pharmaceuticals to Present at the 2021 International Society for Pharmaceutical Engineers Annual Meeting and Expo (PR Newswire)
11.06.21		Ampio Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Summer Healthcare Symposium (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA vor Q3-Ergebnissen: Hohe Erwartungen und höhere Kursziele für den KI-Giganten

Solana noch in diesem Jahr bei 300 US-Dollar?

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

BlackRocks Bitcoin-ETF überholt Gold-ETF

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.11.2024 12:36
Kaufwert:	EUR
	Hinzufügen Speichern